Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Sight Sciences Announces CE Mark Approval for and Successful Commercial Experiences with the VISCO™360 Viscosurgical System for the Surgical Treatment of Glaucoma

Sight Sciences,Inc.
Posted on: 17 Sep 16

PR Newswire

MENLO PARK, California, Sept. 9, 2016

Promising Clinical Results of the New MIGS Procedure in Europe to be Presented by Professor Norbert Körber at the Annual ESCRS meeting in Copenhagen     

MENLO PARK, California, Sept. 9, 2016 /PRNewswire/ -- Sight Sciences, Inc., a venture-backed, commercial stage ophthalmic medical device company announced today that the initial European commercial cases with the CE mark approved VISCO™360 Viscosurgical System will be presented Monday morning, September 12th during the European Society of Cataract and Refractive Surgeons (ESCRS) meeting in Copenhagen, Denmark. The Glaucoma II Session will be in Hall C4 and Prof. Dr. Körber's presentation titled, "VISCO™360 Viscosurgical Instrument for Ab Interno Canaloplasty: Technique and First Results" will begin promptly at 09:10.

"The microcatheterization and viscodilation of Schlemm's canal has been shown to safely and consistently reduce intraocular pressure in adult patients with primary open-angle glaucoma," explains Prof. Dr. Norbert Körber, Professor of Ophthalmology at the Augencentrum in Cologne, Germany and the first physician to use the approved VISCO360 system in Europe. "Ab externo canaloplasty has become a gold standard surgical procedure in Germany because of its effectiveness, but it remains an overly complex procedure for many surgeons. The VISCO360 System simplifies canaloplasty and allows for complete access to Schlemm's canal using an easier, ab interno approach. I look forward to sharing my first experiences with the VISCO360 System in a podium presentation at the upcoming ESCRS meeting."

The VISCO360 System offers ophthalmologists in the EU* a user friendly, clear corneal approach to canaloplasty, a glaucoma procedure with a well established safety and efficacy profile. "Receiving CE mark approval for the VISCO360 System and presenting positive commercial experiences with the device are major milestones for our company and, more importantly, for the treatment of patients with glaucoma," stated Paul Badawi, Founder and CEO of Sight Sciences. "Canaloplasty has always been safe and effective, but adoption has been limited by the surgical complexity and the steep learning curve of the ab externo approach. We're pleased that the VISCO360 System is helping physicians across Europe perform canaloplasty in a more straightforward and less invasive manner."

The VISCO360 System is a fully integrated, single-handed, single-use device specifically designed for an ab interno approach using one single clear corneal incision. The system combines a custom access cannula, a soft and flexible microcatheter with an atraumatic tip, an internal infusion pump and viscoelastic reservoir, and a wheel that controls advancement and retraction of the microcatheter using only a single finger.

Glaucoma is the world's leading cause of irreversible blindness and affects approximately 80 million people worldwide. Often associated with abnormally high intraocular pressure, glaucoma is characterized by progressive vision loss due to irreversible optic nerve damage. It is estimated that 20% of people with glaucoma do have co-existing cataracts while 80% of people with glaucoma do not have co-existing cataracts making a combined or standalone surgical option like VISCO360 an important part of an ophthalmologist's armamentarium.

About Sight Sciences: Sight Sciences is a medical device company dedicated to the development of technology-driven solutions that address the underlying physiology of ophthalmic disease. The company operates two business lines: surgical and non-surgical devices. Its surgical product portfolio consists of the TRAB360 and VISCO360 surgical devices. Its non-surgical product portfolio consists of technologies in the advanced stages of development for evaporative dry eye. For more information, visit www.sightsciences.com.

*The VISCO360 Viscosurgical System is commercially available in the United States as a manual surgical tool but is investigational in the United States for the specific indication of IOP reduction in adult, pseudophakic patients with primary open angle glaucoma.

MEDIA CONTACT:
Katie Arnold
SPRIG Consulting, LLC
+1 (408) 805-0520
katie@sprigconsulting.com

PR Newswire
www.prnewswire.com

Last updated on: 17/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.